Differential regulation by AT(1) and AT(2) receptors of angiotensin II-stimulated cyclic GMP production in rat uterine artery and aorta.

Department of Pharmacology, Monash University, Clayton, Victoria 3800, Australia.
British Journal of Pharmacology (Impact Factor: 5.07). 04/2004; 141(6):1024-31. DOI: 10.1038/sj.bjp.0705694
Source: PubMed

ABSTRACT 1. In the present study we determined whether angiotensin II (Ang II) could increase cyclic GMP levels in two blood vessels that exhibit markedly different angiotensin II receptor subtype expression: rat uterine artery (UA; AT(2) receptor-predominant) and aorta (AT(1) receptor-predominant), and investigated the receptor subtype(s) and intracellular pathways involved. 2. UA and aorta were treated with Ang II in the absence and presence of losartan (AT(1) antagonist; 0.1 microm), PD 123319 (AT(2) antagonist; 1 microm), NOLA (NOS inhibitor; 30 microm), and HOE 140 (B(2) antagonist; 0.1 microm), or in combination. 3. Ang II (10 nm) induced a 60% increase in UA cyclic GMP content; an effect that was augmented with PD 123319 and HOE 140 pretreatment, and abolished by cotreatment with losartan, as well as by NOLA. 4. In aorta, Ang II produced concentration-dependent increases in cyclic GMP levels. Unlike effects in UA, these responses were abolished by PD 123319 and by NOLA, whereas losartan and HOE 140 caused partial inhibition. 5. Thus, in rat UA, Ang II stimulates cyclic GMP production through AT(1) and, to a less extent, AT(2) receptors. In rat aorta, the Ang II-mediated increase in cyclic GMP production is predominantly AT(2) receptor-mediated. In both preparations, NO plays a critical role in mediating the effect of Ang II, whereas bradykinin has differential roles in the two vessels. In UA, B(2) receptor blockade may result in a compensatory increase in cyclic GMP production, whilst in aorta, bradykinin accounts for approximately half of the cyclic GMP produced in response to Ang II.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In 1989, the development of specific angiotensin receptor antagonists which distinguish between two angiotensin receptor subtypes (AT1 and AT2) led to a breakthrough in angiotensin research. It turned out, that the AT1 receptor was almost entirely responsible for the "classical" actions of angiotensin II related to the regulation of blood pressure as well as volume and electrolyte balance. However, actions and signal transduction mechanisms coupled to the AT2 receptor remained enigmatic for a long time. The present review summarizes the current knowledge of AT2 receptor distribution, signaling and function with an emphasis on growth/anti-growth, differentiation and the regeneration of neuronal tissue.
    Peptides 09/2005; 26(8):1401-9. · 2.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Endothelial dysfunction is considered a surrogate marker for cardiovascular disease. Angiotensin II, the principal hormone of the renin angiotensin system, is known to promote atherogenesis. However, other angiotensin peptide fragments such as angiotensin IV possess biological activity that may in fact counter-regulate the actions of angiotensin II. Therefore, we investigated the role of angiotensin IV on the development of endothelial dysfunction in apolipoprotein E-deficient (ApoE-/-) mice. In contrast to their wild-type control, ApoE-/- mice that were fed a high-fat diet had exacerbated endothelial dysfunction, evidenced by impaired endothelium-dependent vasodilation. Chronic infusion of angiotensin IV (1.44 mg/kg per day) in ApoE-/- mice for 2 weeks resulted in significant improvements in endothelial function. Angiotensin IV treatment markedly decreased superoxide levels (dihydroethidium staining fluorescence and L-012 chemiluminescence) and increased endothelial nitric oxide synthase expression (immunoreactivity and western blotting) in aortic tissue. Co-treatment of angiotensin IV with either AT4 receptor antagonist divalinal-Ang IV or AT2 receptor antagonist PD123319 attenuated these changes, indicating involvement of both the AT4 and the AT2 receptors. Chronic angiotensin IV treatment in ApoE-/- mice evoked a marked vasoprotective effect that appeared to be mediated by improved NO bioavailability as a result of AT4 and/or AT2 receptor stimulation.
    Cardiovascular Research 02/2008; 77(1):178-87. · 5.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recently, we have demonstrated that 13-cis retinoic acid (13cRA) down-regulates rat angiotensin type 1A receptor (AT1AR) gene transcription through a MAP Kinase (ERK1/2) dependent mechanism in rat liver epithelial and aortic smooth muscle cells. However, the exact mechanism remained unknown. In this study, we determined the signaling intermediates activated by ERK1/2 involved in 13cRA mediated AT1AR down-regulation. Serially deleted rat AT1AR promoter CAT constructs indicate fragments containing a region -2541 and -1836 bp upstream of the 5 prime possess an Sp1 consensus sequence (5'-TGGGGCGGGGCGGGG-3') have reduced CAT activity. Mobility shift analysis using untreated nuclear extracts in the presence of mithramycin A suggest the trans-acting factor binding to this cis-acting element is Sp1. 13cRA significantly reduced specific binding without any change in Sp1 protein expression. Studies showed 13cRA maximally phosphorylates and tranlocates to the nucleus ERK1/2 within 5-10 minutes, activating Egr-1 mRNA expression at 20 minutes followed by de novo protein synthesis, leading to an Egr-1/Sp1 interaction. siRNA silencing of Egr-1 restored AT1AR mRNA and protein expression in 13cRA treated cells, and Sp1 silencing results in complete loss of AT1AR expression. Our study suggests that 13cRA mediated activation of ERK1/2, through Egr-1, is capable of disrupting Sp1, the requisite transactivator for AT1AR expression, providing a novel paradigm in AT1AR gene transcription.
    Journal of Molecular Endocrinology 03/2013; · 3.58 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014